LRRC4B Inhibitors
LRRC4B, or Leucine-Rich Repeat Containing 4B, is a member of the leucine-rich repeat (LRR) protein family, which plays important roles in a variety of biological processes, including cell adhesion, signal transduction, and immune responses. The LRR motifs are typically involved in protein-protein interactions, suggesting that LRRC4B may function in mediating communication between cells or in the assembly of cellular complexes. Given its structural characteristics, LRRC4B likely contributes to the maintenance of cellular architecture and the regulation of signaling pathways that are critical for cellular function and development. The specific roles of LRRC4B are still under investigation, but it is thought to be involved in the nervous system development based on its expression patterns and the known functions of closely related proteins.
The inhibition of LRRC4B can disrupt normal cellular and developmental processes, potentially leading to various physiological disturbances. This inhibition can occur through several mechanisms. Genetic regulation plays a key role, where transcription factors that normally promote LRRC4B expression could be inhibited, or epigenetic changes might modify the chromatin structure around the LRRC4B gene, reducing its transcriptional activity. Additionally, post-transcriptional regulation such as mRNA degradation could lower LRRC4B levels, impacting its protein synthesis. At the protein level, modifications like phosphorylation, ubiquitination, or other forms of post-translational modifications could affect the stability, localization, or functionality of LRRC4B. For instance, ubiquitination might target it for proteasomal degradation, significantly reducing its functional presence in the cell. Another potential inhibitory mechanism is the competitive or allosteric inhibition of protein-protein interactions involving LRRC4B, which would hinder its role in cellular signaling pathways and structural maintenance. These inhibitory processes are critical to understand as they could have broad implications on cellular communication and integrity, especially within the context of neurodevelopment and the functioning of the nervous system.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor known to block PI3K-dependent phosphorylation of Akt, thereby halting downstream activities like cell proliferation and survival. If LRRC4B interacts with the PI3K-Akt pathway or proteins within this pathway, inhibition by Wortmannin could substantially influence its role in the cellular context. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 selectively inhibits MEK1 and MEK2, key components of the MAPK/ERK pathway. This compound would consequently block any ERK activation, impacting processes such as cell differentiation and growth. If LRRC4B operates within or downstream of this pathway, its activity would be hindered. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $70.00 $215.00 | 26 | |
This compound mimics glucose but inhibits hexokinase, the first enzyme in the glycolytic pathway. By doing so, it disrupts ATP production, leading to an energy crisis in the cell. If LRRC4B functions are dependent on ATP-sensitive cellular processes, then 2-Deoxyglucose can indirectly inhibit LRRC4B's functional integrity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. The p38 MAPK pathway is often activated by stress stimuli like cytokines. Inhibition of this pathway will downregulate inflammatory responses, and if LRRC4B is part of this stress response mechanism, its activity could be hampered. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Similar to Wortmannin, LY294002 inhibits PI3K. By inhibiting PI3K, this compound prevents the phosphorylation of PIP2 to PIP3, a crucial step in the activation of the Akt pathway. If LRRC4B is involved in this pathway or interacts with Akt, its functions would be interrupted. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a specific inhibitor of Rho-associated coiled-coil forming kinases (ROCKs). ROCKs are involved in multiple cellular functions including cell motility. If LRRC4B plays a role in cellular movement or cytoskeleton organization, Y-27632 can indirectly affect its activity. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is a potent Src family kinase inhibitor. It selectively inhibits Src, Fyn, and Yes, which are involved in a multitude of signaling pathways. Should LRRC4B interact with Src or be implicated in Src-dependent pathways like cell adhesion or migration, its function would be diminished. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits the mTOR complex, a key regulator of cell growth and survival. This could influence LRRC4B if the protein plays a role in cellular proliferation or autophagy, as these processes are tightly regulated by mTOR. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a broad-spectrum kinase inhibitor that has the ability to inhibit a range of protein kinases. As such, if LRRC4B's function is directly or indirectly dependent on any protein kinases, its activity would be impeded by Staurosporine. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor. By inhibiting the proteasome, this chemical prevents the degradation of ubiquitinated proteins. If LRRC4B is subject to ubiquitination for its function or stability, this inhibitor would alter its activity. | ||||||